Z
Zerion Pharma develops novel excipients through its Dispersome® platform to formulate poorly soluble small molecule drugs into stable amorphous formulations. This technology increases drug solubility and dissolution rate, aiming to improve patient bioavailability and therapeutic outcomes. The resulting formulations are compatible with standard solid oral dosage form manufacturing processes.
Copenhagen, Denmark
Updated 2 months ago
Funding
$4.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Zerion Pharma develops novel excipients through its Dispersome® platform to formulate poorly soluble small molecule drugs into stable amorphous formulations. This technology increases drug solubility and dissolution rate, aiming to improve patient bioavailability and therapeutic outcomes. The resulting formulations are compatible with standard solid oral dosage form manufacturing processes.